These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15848575)

  • 1. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study.
    Mourad G; Rostaing L; Legendre Ch;
    Transplant Proc; 2005 Mar; 37(2):920-2. PubMed ID: 15848575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function.
    Douzdjian V; Bhaskar S; Baliga PK; Rajagopalan PR
    Clin Transplant; 1997 Aug; 11(4):294-8. PubMed ID: 9267718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
    Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
    Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
    Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
    Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
    Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
    Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study.
    Lebranchu Y; Halimi JM; Bock A; Chapman J; Dussol B; Fritsche L; Kliem V; Oppenheimer F; Pohanka E; Salvadori M; Soergel M; Tufveson G;
    Transplant Proc; 2005; 37(1):345-7. PubMed ID: 15808638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
    Vincenti F; Tuncer M; Castagneto M; Klinger M; Friman S; Scheuermann EH; Wiecek A; Russ GR; Martinek A; Nonnast-Daniel B;
    Transplant Proc; 2005 Mar; 37(2):1001-4. PubMed ID: 15848604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO; Dias MF; Pacheco-Silva A
    Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation.
    Boggi U; Vistoli F; Del Chiaro M; Croce C; Morelli L; Coletti L; Signori S; Giannarelli R; Marchetti P; Del Prato S; Rizzo G; Mosca F
    Transplant Proc; 2004 May; 36(4):1064-6. PubMed ID: 15194369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sequential protocols with thymoglobuline and delayed introduction of calcineurin: effects on renal function in renal transplant recipients with non immunological risk and low risk of delayed graft function].
    Ricard-Sutra E; Garrigue V; Bismuth J; Chong G; Argiles A; Mourad G
    Nephrologie; 2004; 25(4):127-32. PubMed ID: 15291140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.